Psychedelic Business Spotlight: October 15
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
Psychedelic Spotlight News
-
-
Indigenous People and Psychedelics Can Teach Us ‘One of the Most Important Lessons’ Society Has Forgotten
Ethnobotanist Joseph Mays discusses “the key to all life,” and Indigenous reciprocity on the latest Psychedelic Spotlight Podcast episode.
-
Psychedelic Use Associated with Reduced Risk of Heart Disease and Diabetes
Researchers say there are several ways classic psychedelics could, directly and indirectly, lead to improved cardiometabolic health.
-
Why Are Psychedelic Stocks Falling? (MindMed, Atai, Cybin, FieldTrip, Compass Pathways)
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), atai Life Sciences (atai: NASDAQ), Field Trip (FTRP: TSE) ( FTRP: NASDAQ), Cybin (CYBN: NYSE) and many more have experienced a decline in stock prices. So in this episode, we’ll be discussing the reasons behind this and whether we are ignoring some red flags.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestorWant to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.comMusic from:
www.bensound.comVideo editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #FieldTrip #PsychedelicStocks
-
Why Psychedelic Stocks Have Crashed in the Last 3 Months
Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
-
FDA Backs Ketamine to Treat This Rare and Debilitating Pain Syndrome
Food and Drug Administration grants psychedelic biotechnology company PharmaTher orphan drug designation for ketamine to treat complex regional pain syndrome.
-
Interview with Joseph Mays, IRI Program Director at Chacruna
In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.
-
You Can Now Buy Marley One Functional Mushrooms on Amazon
Silo Wellness CEO Douglas K. Gordon tells Psychedelic Spotlight that this is a “crucial” step toward “the mainstream acceptance of psychedelics and overall de-stigmatization of mushrooms, by way of the functional category.”
-
Pennsylvania Lawmakers File Psilocybin Research Bill for Veterans and First Responders
“As traditional treatment has proven inadequate at both the individual and public health level, the Commonwealth has a responsibility to research alternative options,” the bill’s sponsors write in a memo.
-
On Sacred Reciprocity: Giving Back to our Indigenous Predecessors in the Psychedelic Movement
We owe so much of our understanding of these compounds to Indigenous peoples, and the widespread bioprospecting projects taking place today would not be prevalent without the inherent harm placed on local groups historically.
